Evidence map›Paper›PMID 32451752›Full record

ReviewTargeted oncology2020

MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside.

Margherita Ratti, Andrea Lampis, Michele Ghidini, Massimiliano Salati, Milko B Mirchev, Nicola Valeri, Jens C Hahne

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Targeted oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 343 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
343citing papers in PubMed, 4 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

343 citing papers in PubMed, 4 syntheses or guidelines pooled it, 548 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

283 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Margherita RattiDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Andrea LampisDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Michele GhidiniDivision of Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Massimiliano SalatiDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Milko B MirchevClinic of Gastroenterology, Medical University, Varna, Bulgaria.
Nicola ValeriDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Jens C HahneDivision of Molecular Pathology, The Institute of Cancer Research, London, UK. Jens.Hanhe@icr.ac.uk.ORCID 0000-0002-1425-7486
Institute of Cancer Research · GBFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITMedical University of Varna · BGRoyal Marsden NHS Foundation Trust · GB

Funding

Cancer Research UK 18052
6 · The paper itself

Abstract

Non-coding RNAs represent a significant proportion of the human genome. After having been considered as 'junk' for a long time, non-coding RNAs are now well established as playing important roles in maintaining cellular homeostasis and functions. Some non-coding RNAs show cell- and tissue-specific expression patterns and are specifically deregulated under pathological conditions (e.g. cancer). Therefore, non-coding RNAs have been extensively studied as potential biomarkers in the context of different diseases with a focus on microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) for several years. Since their discovery, miRNAs have attracted more attention than lncRNAs in research studies; however, both families of non-coding RNAs have been established to play an important role in gene expression control, either as transcriptional or post-transcriptional regulators. Both miRNAs and lncRNAs can regulate key genes involved in the development of cancer, thus influencing tumour growth, invasion, and metastasis by increasing the activation of oncogenic pathways and limiting the expression of tumour suppressors. Furthermore, miRNAs and lncRNAs are also emerging as important mediators in drug-sensitivity and drug-resistance mechanisms. In the light of these premises, a number of pre-clinical and early clinical studies are exploring the potential of non-coding RNAs as new therapeutics. The aim of this review is to summarise the latest knowledge of the use of miRNAs and lncRNAs as therapeutic tools for cancer treatment.

Indexed as

HumansMicroRNAsNeoplasmsRNA, Long NoncodingMicroRNAsRNA, Long Noncoding

Identifiers

PMID32451752
PMCPMC7283209
OpenAlexW3030635214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.